AC BioScience Ltd is a clinical stage biotechnology company dedicated to developing innovative therapies for the treatment of tumoral and immunological pathologies.
Products, services, technology
S1P metabolites (ACB2003.4) as an angiogenic therapy for solid hypoxic cancers. Start with clinical trials Phase 2/3 in early 2022 for a combination treatment of metastatic pancreatic adenocarcinoma.
Beta-carboline derivative (ACB1801) to enhance the efficacy of checkpoint-inhibitor immune-therapy.